Junji Furuse

28.6k total citations · 7 hit papers
421 papers, 12.7k citations indexed

About

Junji Furuse is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Junji Furuse has authored 421 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Oncology, 161 papers in Surgery and 142 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Junji Furuse's work include Pancreatic and Hepatic Oncology Research (168 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (134 papers) and Hepatocellular Carcinoma Treatment and Prognosis (110 papers). Junji Furuse is often cited by papers focused on Pancreatic and Hepatic Oncology Research (168 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (134 papers) and Hepatocellular Carcinoma Treatment and Prognosis (110 papers). Junji Furuse collaborates with scholars based in Japan, United States and South Korea. Junji Furuse's co-authors include Takuji Okusaka, Hiroshi Ishii, Masafumi Ikeda, Christos N. Papandreou, Laura Ladrón de Guevara, Alan P. Venook, Chigusa Morizane, Masatoshi Kudo, Makoto Ueno and Kohei Nakachi and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Junji Furuse

396 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

2010 790 citations Alan P. Venook, Christos N. Papandreou et al. profile →
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

2010 541 citations Takuji Okusaka, Kohei Nakachi et al. profile →
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Masatoshi Kudo, Junji Furuse et al. profile →
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

2018 379 citations Hideki Ueno, Junji Furuse et al. profile →
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

2020 274 citations Bruno Sangro, Richard S. Finn et al. Journal of Hepatology profile →
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Stephen L. Chan, Masatoshi Kudo et al. Journal of Clinical Oncology profile →
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

2019 247 citations Makoto Ueno, Masafumi Ikeda et al. profile →

Peers

Countries citing papers authored by Junji Furuse

Since Specialization

Citations

This map shows the geographic impact of Junji Furuse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junji Furuse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junji Furuse more than expected).

Fields of papers citing papers by Junji Furuse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junji Furuse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junji Furuse. The network helps show where Junji Furuse may publish in the future.

Co-authorship network of co-authors of Junji Furuse

This figure shows the co-authorship network connecting the top 25 collaborators of Junji Furuse. A scholar is included among the top collaborators of Junji Furuse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junji Furuse. Junji Furuse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment 2025 ·European Journal of Cancer ·Hiroshi Imaoka, Masafumi Ikeda, Masato Ozaka, (unknown), Naohiro Okano, Satoshi Shimizu, Hidetaka Tsumura, Yoshito Komatsu, (unknown), (unknown), Hiroaki Nagano, Terumasa Hisano, Mitsuhito Sasaki, Satoshi Kobayashi, Taito Fukushima, Shuichi Mitsunaga, Takaaki Furukawa, Satoshi Hamauchi, Makoto Ueno, Junji Furuse	0
2	Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice 2025 ·Cancers ·Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, (unknown), (unknown), Masatoshi Kudo	0
3	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) 2024 ·Annals of Oncology ·(unknown), Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, (unknown), Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, (unknown), Shukui Qin	0
4	Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report 2024 ·Case Reports in Gastroenterology ·(unknown), Makoto Ueno, Satoshi Kobayashi, (unknown), (unknown), Terufumi Kato, Haruhiro Saito, Shinya Sato, Junji Furuse, Shin Maeda	0
5	127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) 2024 ·Annals of Oncology ·Mitsuhiro Kudo, Lorenza Rimassa, (unknown), Bruno Sangro, George Lau, В. В. Бредер, (unknown), Oxana Crysler, (unknown), Tu Van Dao, Adilson Faccio, Junji Furuse, L-B. Jeng, Y-K. Kang, Robin Kate Kelley, Michael J. Paskow, (unknown), Di Ran, Alejandra Negro, (unknown)	1
6	Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients 2024 ·Clinical Cancer Research ·Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, Do‐Youn Oh, John Bridgewater, (unknown), (unknown), (unknown), Volker Wacheck, Lipika Goyal	8
7	Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT. 2024 ·Journal of Clinical Oncology ·Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Junki Mizusawa, Hiroshi Katayama, (unknown), Katsuhiko Uesaka, Hiroaki Yanagimoto, Soichiro Morinaga, Hiroshi Wada, Kazuaki Shimada, Yu Takahashi, (unknown), Kunihito Gotoh, Ken Kamata, Yasuhiro Shimizu, Hiroshi Ishii, Takuji Okusaka, Junji Furuse, Makoto Ueno	1
8	A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy 2024 ·Clinical Cancer Research ·Junji Furuse, Masafumi Ikeda, Makoto Ueno, (unknown), Chigusa Morizane, Tetsuo Takehara, Tomohiro Nishina, Akiko Todaka, Naohiro Okano, Kazuo Hara, Yousuke Nakai, Kazuyoshi Ohkawa, Takashi Sasaki, Kazuya Sugimori, Naoyuki Yokoyama, Kouji Yamamoto	10
9	Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial 2024 ·Journal of Clinical Oncology ·Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura, (unknown), Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka	20
10	1562P Claudin 18.2 expression in resected gastric cancer 2023 ·Annals of Oncology ·(unknown), (unknown), Shinya Sato, (unknown), Takashi Hama, (unknown), Kunihiko Hayashi, (unknown), (unknown), (unknown), Shinsuke Nagasawa, Ken Kanematsu, Takanobu Yamada, Takashi Ogata, Takashi Oshima, Yohei Miyagi, Tomoyuki Yokose, Nozomu Machida, Junji Furuse	3
11	Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer 2023 ·Anticancer Research ·Kei Hayashi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), ITARU HASHIMOTO, (unknown), Shinsuke Nagasawa, (unknown), Takanobu Yamada, Akifumi Notsu, Takashi Ogata, Takashi Oshima, Nozomu Machida, Junji Furuse, Shin Maeda	0
12	Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202 2023 ·European Journal of Surgical Oncology ·Shogo Kobayashi, (unknown), Masafumi Ikeda, Masaru Konishi, Gakuto Ogawa, Teiichi Sugiura, Hiroaki Yanagimoto, Soichiro Morinaga, Hiroshi Wada, Kazuaki Shimada, Yu Takahashi, Toshio Nakagohri, Ken Kamata, Yasuhiro Shimizu, Tetsuo Ajiki, Satoshi Hirano, Naoto Gotohda, Makoto Ueno, Takuji Okusaka, Junji Furuse	3
13	A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index 2022 ·Cancer ·Tateaki Naito, Junji Uchino, Toru Kojima, (unknown), Koichi Minato, Kentaro Tanaka, Takuro Mizukami, Shinji Atagi, Takashi Higashiguchi, Kei Muro, Koichi Takayama, Junji Furuse, (unknown), Toru Takiguchi, Kazuo Tamura	31
14	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version) 2022 ·Hepatology Research ·Masatoshi Kudo, Masafumi Ikeda, Kazuomi Ueshima, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Kazuhiro Nouso, Kiyoshi Hasegawa, Junji Furuse, Shiro Miyayama, Takamichi Murakami, Tatsuya Yamashita, Norihiro Kokudo	12
15	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines 2020 ·Journal of Gastroenterology ·Takuji Okusaka, Junji Furuse	63
16	A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial) 2020 ·Neuroendocrinology ·Hiroyuki Okuyama, Masafumi Ikeda, Takuji Okusaka, Masayuki Furukawa, Shinichi Ohkawa, Ayumu Hosokawa, Yasushi Kojima, Hiroki Hara, (unknown), Kazuhiko Shioji, Akinori Asagi, Nobumasa Mizuno, Motohiro Kojima, Takeharu Yamanaka, Junji Furuse	17
17	First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors 2019 ·Cancer Science ·Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, (unknown), Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto	24
18	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1 2018 ·Pancreas ·Yasunori Sato, Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Masafumi Ikeda, T Shimamura, Akihito Tsuji, Yoshiaki Tsuchiya, Junji Furuse, Hiroshi Ishii, Ken Furuya, Haruo Iguchi, Yoshihiro Saito, Nahoko Kaniwa, Jun‐ichi Sawada, Hiromi Sakamoto, Akihiro Sekine, Takuji Okusaka, Teruhiko Yoshida	3
19	Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study 2016 ·Journal of Hepatology ·Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao‐Ping Chen, Lucy Dagher, Junji Furuse, Jean-François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni	264
20	Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival 2012 ·Clinical Cancer Research ·Yu Sawada, Toshiaki Yoshikawa, Daisuke Nobuoka, Hirofumi Shirakawa, (unknown), Yutaka Motomura, Shoichi Mizuno, Hiroshi Ishii, Kohei Nakachi, Masaru Konishi, Toshio Nakagohri, Shinichiro Takahashi, Naoto Gotohda, Tadatoshi Takayama, Kenji Yamao, Katsuhiko Uesaka, Junji Furuse, Taira Kinoshitá, Tetsuya Nakatsura	251

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact